y*****l
发帖数: 5997 | 1 Celera, Abbott in exclusive distribution deal - Stock To Watch
9/20/2010 8:59:15 AM
(RTTNews) Celera Corp. (CRA) said it signed an exclusive distribution
agreement to market its CE-marked KIF6 diagnostic test for use on Abbott’s
(ABT) CE-marked m2000 instrument system. Financial details of the agreement
were not disclosed.
The KIF6 genotyping assay detects a genetic marker that may be used in
conjunction with clinical evaluation and patient assessment for identifying
individuals at risk for coronary heart disease or CHD, and in patients for
whom statin treatment is being considered.
Previous research has shown that a variant of the KIF6 gene is associated
with up to a 55% increased risk of primary and recurrent CHD events, and
that this increased risk was significantly reduced with statin therapy.
"Celera’s KIF6 test represents the first cardiovascular assay on the m2000
system", comments Abbott.
The deal follows the application by Celera for the CE mark in June 2010.
This is the first of Celera’s proprietary cardiovascular genetics products
to be CE marked.
Under the 4-year agreement, Celera will manufacture the KIF6 test kit that
Abbott will distribute in the European Union, other geographic areas that
recognize the CE mark, and elsewhere worldwide, excluding the U.S.
by RTT Staff Writer |
|
